In this GENcast, our guest will tell us more about HTS using 3D cell models and why they are so crucial for current drug discovery projects. Moreover, he will provide scientific insight into the 3D cell panel screening service—called OncoSignature™—which uses a library of 200 cell lines grown in 3D spheroids to provide a better understanding of candidate cancer therapeutics.
In this GEN webinar, we will hear about some of the latest advances in high-throughput analytics, with particular attention on the High-Throughput Impurity Detection platform for automated impurity quantitation from Lonza.
In this GEN webinar, we will learn from Dr. Daniel Lauster, who, when faced with many of the challenges described above, utilized MicroScale Thermophoresis (MST) to measure the interaction between more than 100 novel non-toxic multivalent nanoparticle-conjugates and intact IAV in solution with as little as nanomoles of nanoparticles. Additionally, we will hear from Dr. Matthias Molnar how MST is becoming scientists’ first choice for the characterization of molecular interactions thanks to its flexible throughput, low sample consumption, and measurements in solution or in close to native conditions.
In this GEN webinar, we will hear from Danica Stanimirovic MD, PhD, and Danica Stanimirovic MD, PhD, wto leading scientists who will describe their current antibody engineering research projects and the therapeutic potential they hold.
While the importance of ligand-receptor binding kinetics on drug action is becoming well established, focus to date has been almost entirely on the role of the dissociation constant on drug efficacy and duration of action. The association rate constant, in contrast, has been largely overlooked, with many investigators still considering it diffusion-limited and equivalent across a compound series. This GEN webinar aims to remedy that by turning the spotlight onto the undervalued and oft-ignored association rate constant.
REGISTER NOW Broadcast Date: February 5, 2019Time: 8:00 am PT, 11:00 am ET, 17:00 CET Antibody-drug conjugates select ADCs) were initially developed to provide a selective targeting mechanism...
In this GEN webinar, sponsored by TriLink Biotechnologies, we will hear about data innovations from seven years of research at Novartis Vaccines on self-amplifying mRNA technology and how this approach could enable the concept of vaccines on demand as a rapid response to a real threat rather that the deployment of strategic stockpiles based on epidemiological predictions of a possible threat.
In this GEN webinar, we will discuss how the VIPS™ (Verified in-situ Plate Seeding) system, in combination with the SAL Scientific single-cell cloning supplements, offer customers a high-efficiency solution which ensures plates are populated with high numbers of healthy single cells that grow into resultant colonies for screening, expansion and further selection to master cell banks.
In this GEN webinar, we will discuss some typical workflows used to characterize the properties of vaccines, looking at properties such as particle size, surface charge, aggregation, and protein secondary structure.